Published in Vaccine Weekly, May 18th, 1998
The drug has been in Phase I trials on 30 patients at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles since September 1997.
Called SU5416, the drug developed by Sugen Inc., Redwood City, California, is an angiogenesis inhibitor, which like other recently publicized treatments, completely wiped out tumors in mice, they said.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.